Zhejiang-based Vimgreen Pharma has announced the launch of a Phase II clinical trial for its innovative A2AR antagonist VG081821AC, targeting early to mid-stage Parkinson’s disease (PD). The company has successfully completed patient dosing for the study.
This 12-week, multi-center, randomized, double-blinded trial aims to evaluate the safety and efficacy of VG081821AC administered alone in early to mid-stage PD patients. A total of 15 subjects have been enrolled and randomly assigned to one of three groups: a high-dose VG081821AC group, a low-dose VG081821AC group, and a placebo group, in a 1:1:1 ratio. The primary endpoint focuses on the change in the MDS-UPDRS Part III (Motor Symptoms) score from baseline to the end of the 12-week dosing period, compared to placebo. The trial is projected to conclude in November.
Current treatment options for Parkinson’s disease predominantly involve dopamine replacement therapy, which is often associated with long-term side effects such as diminished efficacy, the on-off phenomenon, and dyskinesia. VG081821AC, a non-dopamine therapeutic, is anticipated to mitigate or delay these adverse effects when used early in the treatment process, while also aiming to modify the disease and slow its progression.- Flcube.com
